BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ for PLASMA PROTEIN THERAPEUTICS ASSOCIATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FY16 FDA Agriculture-Rural Development appropriations bill, provisions related to plasma protein therapies; H.R. 1600, Patients Access to Treatment Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICOLE CARELLI | — |
| CAROLINE SELBY New | — |
Medicare/Medicaid MMM
Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; Medicare reimbursement methodology for DME infused drugs, generally.
| Lobbyist | Covered position, as disclosed |
|---|---|
| NICOLE CARELLI | — |
| CAROLINE SELBY New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.